This prospective chart review study (2011)(2012)(2013) from Texas included infants aged #60 days with a positive culture from the blood, urine, or cerebrospinal fluid. The researcher' s objectives were to study the pathogens and the optimal choice of antibiotics in infants with serious bacterial infection (SBI).
The authors noted that when meningitis was not suspected, regimens of either ampicillin/gentamicin or a thirdgeneration cephalosporin were equally effective based on susceptibility data (96% and 97%). They also noted that 67% of cases in which a third-generation cephalosporin was used resulted in unnecessarily broad coverage compared with ampicillin/gentamicin. Also, 57% of third-generation courses were continued despite susceptibility results allowing deescalation of therapy.
Why do we care?
Hospitalized infants with fever and suspected SBI are our wheelhouse. We love third-generation cephalosporins, especially for infants aged 29 days and older. This study suggests that for infants in whom meningitis is not suspected, we should be using gentamicin instead of a cephalosporin to avoid antibiotic resistance. Our love for cephalosporins may also be preventing us from narrowing our coverage once susceptibilities are known.
STRAIGHT FROM THE AUTHOR …
We reached out to Dr J.B. Canty, the lead author of the study, and asked him these questions: What about gentamicin' s side effects? and What about checking gentamicin levels? Here is his response:
"As user-friendly as third-generation cephalosporins can be, they come with a cost: exposure of the infant' s normal gut flora to cephalosporins leads to both the development of drug resistance and the elimination of protective commensal organisms. In turn, this leads to increased infections with resistant organisms and yeast down the road. While these side effects are seen most easily in closed systems such as the neonatal intensive care unit, it is important to remember that the community is just a big closed system! The use of aminoglycosides has not been associated with these adverse outcomes. Admittedly aminoglycoside levels are an extra burden on the infant, but only those infants who have a culture-proven SBI that requires aminoglycoside therapy will require levels. For most infants, the empiric therapy will be discontinued or narrowed before levels are needed. Finally, third-generation cephalosporins are needed when meningitis is suspected, but it is critical to obtain cerebrospinal fluid before starting antibiotic therapy to prevent infants from being 'stuck' on unnecessarily broad cephalosporin therapy."
CITATION Cantey JB, Lopez-Medina E, Nguyen S, Doern C, Garcia C. A multivariate regression showed that the likelihood of AKI increased with each 5-mg/kg increase in vancomycin dose (OR 5 1.16; 95% CI 5 1.01-1.33) and with each additional day of therapy (OR 5 1.11; 95% CI 5 1.01-1.22). In all models, concurrent use of nephrotoxic medications and longer durations of therapy were associated with increased odds of AKI.
Why do we care?
With higher vancomycin dosing for many infections after 2009 Infectious Diseases Society of America recommendations 1 and evidence mounting that even transient AKI in childhood is associated with deleterious effects later in life, 2 it is more important than ever to give forethought to prevention of AKI in children receiving vancomycin. As hospitalists, we should be at the center of quality improvement initiatives using systems of care to prevent harm. Potential avenues for improvement include prompts to discontinue antibiotics as soon as medically reasonable, changes to less toxic antibiotics, and avoidance of other nephrotoxic medications while prescribing vancomycin. 
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